Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-27T20:19:41.275Z Has data issue: false hasContentIssue false

5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides

Published online by Cambridge University Press:  29 January 2018

David Murray Shaw
Affiliation:
M.R.C. Neuropsychiatric Research Unit, Carshalton and West Park Hospital, Epsom, Surrey
Francis E. Camps
Affiliation:
The London Hospital Medical College, Whitechapel, E.1
Eric G. Eccleston
Affiliation:
M.R.C. Neuropsychiatric Research Unit, Carshalton and West Park Hospital, Epsom, Surrey

Extract

There is growing evidence of a connection between the metabolism of monoamines and severe depressive illness, but the exact role of these substances in affective disorders has yet to be defined. We know that reserpine depletes the brain of monoamines and that a proportion of patients treated with this compound develop a depressive illness. Conversely a number of compounds which raise the levels of amines in the brain by blocking the enzyme monoamine oxidase have been used in antidepressant therapy. The knowledge that loss of amines may be associated with depression, and that their replenishment in the brain may induce recovery, immediately leads to the question as to which of the biogenic amines is responsible for the affective changes. Pollin, Cardon and Kety (1961) observed the effect of giving various amino acids together with a monoamine oxidase inhibitor (M.A.O.I.) to patients suffering from chronic schizophrenia. They found that only tryptophan, the precursor of the monoamine 5-hydroxytryptamine (5HT), produced an elevation of mood. On the basis of their results, Coppen, Shaw and Farrell (1963) treated a number of patients suffering from severe depressive illness with M.A.O.I. and half of this group also received an oral dose of a suspension of D L-tryptophan (214 mg./kg. body weight) for one week. The patients taking tryptophan and M.A.O.I. recovered more rapidly than those receiving M.A.O.I. alone both while they were on tryptophan and also subsequently. One explanation for these findings was that the combination of M.A.O.I. and tryptophan increased the amount of amines derived from tryptophan in the brain, and that it was this which was responsible for the therapeutic effect. If this were so, then there were several possibilities. The first was that the level of 5HT in the brain was low in depression and the combination of amine precursor and enzyme inhibitor brought it back to normal. Alternatively it may be that recovery occurred as a result of the presence of abnormally large quantities of 5HT in the central nervous system or even following the production of tryptamine, another amine derived from tryptophan.

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Sharman, D. F., MacDougall, E. J., Stanton, J. B., and Binns, J. K. (1966). “5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases.” Lancet, ii, 10491052.CrossRefGoogle Scholar
Ashcroft, G. W., and Sharman, D. F. (1960). “5-hydroxyindoles in human cerebrospinal fluids.” Nature (Lond.), 186, 1050.CrossRefGoogle Scholar
Coppen, A., Shaw, D. M., and Farrell, J. P. (1963). “Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan.” Lancet, i, 7981.CrossRefGoogle Scholar
Coppen, A., Shaw, D. M., and Farrell, J. P. Malleson, A., Eccleston, E., and Gundy, G. (1965). “Tryptamine metabolism in depression.” Brit. J. Psychiat., 111, 993998.CrossRefGoogle Scholar
Dencker, S. J., Malm, U., Roos, B.-E., and Werdinius, B. (1966). “Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania.” J. Neurochem., 13, 15451548.CrossRefGoogle Scholar
Joyce, D. (1962). “Changes in the 5-hydroxytryptamine content of rat, rabbit, and human brain after death.” Brit. J. Pharmacol., 18, 370380.Google Scholar
Maclean, R., Nicholson, W. J., Pare, C. M. B., and Stacey, R. S. (1965). “Effect of monoamine-oxidase inhibitors on the concentrations of 5-hydroxytryptamine in the human brain.” Lancet, ii, 205208.CrossRefGoogle Scholar
Pollin, W., Cardon, P. V., and Kety, S. S. (1961). “Effects of amino acid feedings in schizophrenic patients treated with iproniazid.” Science, 133, 104105.CrossRefGoogle Scholar
Udenfriend, S., Weissbach, H., and Brodie, B. B. (1958). Methods of Biochemical Analysis, 6, 95. Ed. Glick, David, New York: Interscience Publishers Inc.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.